Rebecca C. Fitzgerald

Rebecca C. Fitzgerald

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Rebecca C. Fitzgerald

Early Cancer Institute, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2022 in Science
Verified
Journal Article
Closed access
DCDavid Crosby
David Crosby
SBSangeeta Bhatia
Sangeeta Bhatia
KBKevin Brindle
Kevin Brindle
LCLisa M. Coussens
Lisa M. Coussens
CDCaroline Dive
Caroline Dive
SBShankar Balasubramanian
Shankar Balasubramanian
Survival improves when cancer is detected early. However, ~50% of cancers are at an advanced stage when diagnosed. Early detection of cancer or precancerous change allows early intervention to try to slow or prevent cancer development and lethality. To achieve early detection of all cancers, numerous challenges must be overcome. It is vital to better understand who is at greatest risk of developing cancer. We also need to elucidate the biology and trajectory of precancer and early cancer to identify consequential disease that requires intervention. Insights must be translated into sensitive and specific early detection technologies and be appropriately evaluated to support practical clinical implementation. Interdisciplinary collaboration is key; advances in technology and biological understanding highlight that it is time to accelerate early detection research and transform cancer survival.

15 May 2015 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
RPRachel S van der Post
Rachel S van der Post
IVIngrid P Vogelaar
Ingrid P Vogelaar
FCFátima Carneiro
Fátima Carneiro
PGParry Guilford
Parry Guilford
DHDavid Huntsman
David Huntsman
RFRebecca C Fitzgerald
Rebecca C Fitzgerald
Germline CDH1 mutations confer a high lifetime risk of developing diffuse gastric (DGC) and lobular breast cancer (LBC). A multidisciplinary workshop was organised to discuss genetic testing, surgery, surveillance strategies, pathology reporting and the patient's perspective on multiple aspects, including diet post gastrectomy. The updated guidelines include revised CDH1 testing criteria (taking into account first-degree and second-degree relatives): (1) families with two or more patients with gastric cancer at any age, one confirmed DGC; (2) individuals with DGC before the age of 40 and (3) families with diagnoses of both DGC and LBC (one diagnosis before the age of 50). Additionally, CDH1 testing could be considered in patients with bilateral or familial LBC before the age of 50, patients with DGC and cleft lip/palate, and those with precursor lesions for signet ring cell carcinoma. Given the high mortality associated with invasive disease, prophylactic total gastrectomy at a centre of expertise is advised for individuals with pathogenic CDH1 mutations. Breast cancer surveillance with annual breast MRI starting at age 30 for women with a CDH1 mutation is recommended. Standardised endoscopic surveillance in experienced centres is recommended for those opting not to have gastrectomy at the current time, those with CDH1 variants of uncertain significance and those that fulfil hereditary DGC criteria without germline CDH1 mutations. Expert histopathological confirmation of (early) signet ring cell carcinoma is recommended. The impact of gastrectomy and mastectomy should not be underestimated; these can have severe consequences on a psychological, physiological and metabolic level. Nutritional problems should be carefully monitored.

5 February 2020 in Nature Genetics
Verified
Journal Article
Open access
PDF file
BRBernardo Rodriguez-Martin
Bernardo Rodriguez-Martin
EAEva G. Alvarez
Eva G. Alvarez
ABAdrian Baez-Ortega
Adrian Baez-Ortega
JZJorge Zamora
Jorge Zamora
FSFran Supek
Fran Supek
JTJose M. C. Tubio
Jose M. C. Tubio
About half of all cancers have somatic integrations of retrotransposons. Here, to characterize their role in oncogenesis, we analyzed the patterns and mechanisms of somatic retrotransposition in 2,954 cancer genomes from 38 histological cancer subtypes within the framework of the Pan-Cancer Analysis of Whole Genomes (PCAWG) project. We identified 19,166 somatically acquired retrotransposition events, which affected 35% of samples and spanned a range of event types. Long interspersed nuclear element (LINE-1; L1 hereafter) insertions emerged as the first most frequent type of somatic structural variation in esophageal adenocarcinoma, and the second most frequent in head-and-neck and colorectal cancers. Aberrant L1 integrations can delete megabase-scale regions of a chromosome, which sometimes leads to the removal of tumor-suppressor genes, and can induce complex translocations and large-scale duplications. Somatic retrotranspositions can also initiate breakage–fusion–bridge cycles, leading to high-level amplification of oncogenes. These observations illuminate a relevant role of 22 L1 retrotransposition in remodeling the cancer genome, with potential implications for the development of human tumors.

19 April 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RFRebecca C. Fitzgerald
Rebecca C. Fitzgerald
AAAntonis C. Antoniou
Antonis C. Antoniou
LFLjiljana Fruk
Ljiljana Fruk
NRNitzan Rosenfeld
Nitzan Rosenfeld

31 December 2019 in Genome Biology
Verified
Journal Article
Open access
PDF file
EME. Madissoon
E. Madissoon
AWA. Wilbrey-Clark
A. Wilbrey-Clark
RMR. J. Miragaia
R. J. Miragaia
KSK. Saeb-Parsy
K. Saeb-Parsy
KMK. T. Mahbubani
K. T. Mahbubani
KMK. B. Meyer
K. B. Meyer
Background: The Human Cell Atlas is a large international collaborative effort to map all cell types of the human body. Single-cell RNA sequencing can generate high-quality data for the delivery of such an atlas. However, delays between fresh sample collection and processing may lead to poor data and difficulties in experimental design. Results: This study assesses the effect of cold storage on fresh healthy spleen, esophagus, and lung from ≥ 5 donors over 72 h. We collect 240,000 high-quality single-cell transcriptomes with detailed cell type annotations and whole genome sequences of donors, enabling future eQTL studies. Our data provide a valuable resource for the study of these 3 organs and will allow cross-organ comparison of cell types. We see little effect of cold ischemic time on cell yield, total number of reads per cell, and other quality control metrics in any of the tissues within the first 24 h. However, we observe a decrease in the proportions of lung T cells at 72 h, higher percentage of mitochondrial reads, and increased contamination by background ambient RNA reads in the 72-h samples in the spleen, which is cell type specific. Conclusions: In conclusion, we present robust protocols for tissue preservation for up to 24 h prior to scRNA-seq analysis. This greatly facilitates the logistics of sample collection for Human Cell Atlas or clinical studies since it increases the time frames for sample processing.

25 August 2021 in Nature
Verified
Journal Article
Closed access
PDF file
LMLuiza Moore
Luiza Moore
ACAlex Cagan
Alex Cagan
TCTim H. H. Coorens
Tim H. H. Coorens
MNMatthew D. C. Neville
Matthew D. C. Neville
RSRashesh Sanghvi
Rashesh Sanghvi
RRRaheleh Rahbari
Raheleh Rahbari